Premature ejaculation
Conditions
Interventions
Trade Name: Paroxetine
Product Name: Paroxetine
Product Code: Seroxat
Pharmaceutical Form: Tablet
Trade Name: Premjact
Product Name: Premjact spray
Product Code: Premjact Spray
Pharmaceutical Form: C
Sponsors
City University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Male over 18-years of age Symptoms of rapid ejaculation for > 6-months Capable of independently completing the questionnaire The subject has given informed consent, for which he has signed and dated the informed consent form The subject must be in a stable relationship for more than 6 months The subject must have only one sexual partner Must attempt sexual intercourse 2-3 times per week (minimum 8 times per month Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Individuals currently undergoing psychiatric treatment New casual relationships Contra-indications for SSRIs MAOI use Poorly controlled epilepsy Concurrent electro-convulsive therapy History of maniaHepatic or renal impairment Retroviral Medication Treatment for rapid ejaculation within the last 3 monthsILET > 3 minutes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To determine which treatment (paroxetine or premjact) improves intravaginal ejaculatory latency time (IELT) after 4 months of active treatment (2 months pharmacology and 2 months modified behavioural therapy);Secondary Objective: Which treatment option did not require any additional treatment at 2 years;Primary end point(s): Delay in intravaginal ejaculatory latency of 3 minutes. Treatment of 120 participants | — |
Countries
United Kingdom
Outcome results
None listed